NYSE$HCA

HCA Holdings Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

HCA Healthcare's financial performance was solid in Q4 2023, driven by strong demand for services and improved cost trends.

HCA Healthcare reported revenues of $17.303 billion and net income of $1.607 billion for the fourth quarter of 2023. The company experienced strong demand for services and improved cost trends, contributing to the positive financial results.

  • Revenues totaled $17.303 billion.
  • Net income attributable to HCA Healthcare, Inc. totaled $1.607 billion, or $5.93 per diluted share.
  • Adjusted EBITDA totaled $3.618 billion.
  • Same facility admissions increased 3.1 percent while same facility equivalent admissions increased 3.9 percent.

Headline financials

Total Revenue

$17.3B

Previous: $15.5B+11.7%
EPS (adj)

$5.90

Previous: $4.64+27.2%
Admissions

544.6K

Previous: 530.3K+2.7%
Number of Hospitals

186

Previous: 182+2.2%
Licensed Beds at End of Period

49.6K

Previous: 49.3K+0.6%
Occupancy

72.5%

Previous: 72.0%+0.7%
Average Length of Stay (days)

4.911

No prior period
Capital Expenditures

-$1.16B

Previous: $1.32B-187.6%
Net Income

$1.86B

Previous: $2.08B-10.6%
Operating Income

$2.35B

Previous: $3.3B-29.0%
Gross Profit

$14.7B

Previous: $13.1B+12.6%
Stock-Based Comp

$57M

Previous: $83M-31.3%

Revenue & EPS history

HCA · Revenue · Quarterly

$17.3B

Q4 2023+11.7%vs Q4 2022
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

The Company issued the following estimated guidance for 2024:

Tailwinds

  • Revenues $67.75 to $70.25 billion
  • Net Income Attributable to HCA Healthcare, Inc. $5.20 to $5.60 billion
  • Adjusted EBITDA $12.85 to $13.55 billion
  • EPS (diluted) $19.70 to $21.20 per diluted share
  • Capital expenditures for 2024, excluding acquisitions, are estimated to be in the range of $5.1 to $5.3 billion.

Headwinds

  • The Company’s 2024 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding patient volumes and payor mix as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
  • The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”
  • Changes in revenues due to declining patient volumes
  • Changes in payer mix (including increases in uninsured and underinsured patients)
  • Potential increased expenses related to labor, supply chain or other expenditures

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+2.9%

Avg return

30 days after

47%

31 / 66 earnings

Positive

+16.1%

Q2 2020

Best reaction

-21.9%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.2%-8.3%-16.8%
Q4 2025+6.2%+3.4%+11.3%
Q3 2025+1.5%+6.4%+11.6%
Q2 2025+0.8%+3.1%+3.8%
Q1 2025-4.0%+1.1%+10.3%
Q4 2024-3.8%+0.7%-2.7%
Q3 2024-10.6%-9.5%-18.5%
Q2 2024+5.7%+9.0%+17.7%
Q1 2024-0.9%-1.5%+1.5%
Q4 2023+6.3%+7.9%+8.7%
Q3 2023-6.5%-6.5%+5.0%
Q2 2023-3.2%-2.9%-3.2%
Q1 2023+5.7%+2.7%+4.3%
Q4 2022-0.6%+2.6%-2.2%
Q3 2022+0.8%+4.3%+10.3%
Q2 2022+9.6%+12.9%+18.6%
Q1 2022-21.9%-21.2%-24.0%
Q4 2021-1.4%-1.1%+5.5%
Q3 2021-7.0%-5.6%-8.1%
Q2 2021+14.5%+14.2%+13.3%
Q1 2021+2.5%+0.7%+4.5%
Q4 2020+3.7%+5.9%+5.6%
Q3 2020-4.4%-9.3%+12.5%
Q2 2020+16.1%+14.6%+21.2%
Q1 2020-5.4%-2.4%-2.2%
Q4 2019+2.6%-2.0%-10.1%
Q3 2019+6.2%+5.3%+10.3%
Q2 2019-8.7%-13.0%-17.4%
Q1 2019-1.1%+0.2%-2.3%
Q4 2018+5.6%+6.1%+5.5%
Q3 2018+3.5%+4.2%+12.0%
Q2 2018+14.9%+14.7%+21.4%
Q1 2018+2.1%+1.9%+7.7%
Q4 2017+3.6%+2.1%+1.9%
Q3 2017+0.9%+0.3%+11.6%
Q2 2017-5.2%-6.6%-7.9%
Q1 2017-1.2%-0.4%-0.1%
Q4 2016+3.4%+5.7%+10.2%
Q3 2016-2.1%-4.5%-9.6%
Q2 2016-1.1%-3.8%-4.8%
Q1 2016-1.7%
Q4 2015+3.1%
Q3 2015-0.1%
Q2 2015-2.8%
Q1 2015-1.2%
Q4 2014-1.7%
Q3 2014-2.1%
Q2 2014+4.1%
Q1 2014-1.2%
Q4 2013-1.0%
Q3 2013-5.1%
Q2 2013+0.1%
Q1 2013+3.8%
Q4 2012-1.1%
Q3 2012+8.0%
Q2 2012+1.1%
Q1 2012-1.1%
Q4 2009+3.5%
Q4 2011+3.5%
Q3 2011+2.6%
Q3 2010+2.6%
Q2 2011-20.6%
Q2 2010-20.6%
Q1 2011-0.2%
Q1 2010-0.2%
Q4 2010-0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro